STD Testing

STD Testing

Global STD Testing Market to Reach US$144.8 Billion by 2030

The global market for STD Testing estimated at US$101.9 Billion in the year 2023, is expected to reach US$144.8 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Chlamydia Testing, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$40.6 Billion by the end of the analysis period. Growth in the Herpes Simplex Virus Testing segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$27.3 Billion While China is Forecast to Grow at 8.2% CAGR

The STD Testing market in the U.S. is estimated at US$27.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.5 Billion by the year 2030 trailing a CAGR of 8.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global STD Testing Market - Key Trends & Drivers Summarized

Why Is STD Testing Gaining Urgency and Attention Worldwide?

The rising prevalence of sexually transmitted diseases (STDs) across the globe has led to a significant increase in demand for STD testing services. Factors such as changing sexual behavior, lack of awareness, and inadequate education on safe practices have contributed to the surge in STD cases. In response, healthcare organizations and governments are promoting early diagnosis and routine testing to curb the spread of infections and improve patient outcomes. The expansion of public health campaigns and increased access to healthcare services, particularly in developing regions, are also contributing to the emphasis on STD testing. With diseases like HIV, chlamydia, gonorrhea, and syphilis being major public health concerns, the importance of accessible, reliable, and rapid testing solutions continues to grow, underscoring the urgent need for comprehensive testing programs worldwide.

How Are Technological Advancements Influencing the STD Testing Landscape?

The STD testing market is being reshaped by technological advancements aimed at improving diagnostic speed, accuracy, and accessibility. Point-of-care (POC) testing devices are becoming increasingly popular, offering rapid results without the need for laboratory processing, which is essential for early intervention and treatment. Molecular diagnostics, such as polymerase chain reaction (PCR) tests, are enhancing the precision of STD detection, allowing for the identification of multiple pathogens from a single sample. Self-testing kits, which can be used privately at home, are also gaining traction as they provide a convenient and discreet way for individuals to manage their sexual health. The integration of mobile health (mHealth) platforms that connect users with healthcare professionals for remote consultations and result interpretation is further enhancing the reach and efficiency of STD testing services, especially in remote or underserved areas.

What Are the Market Trends Influencing the Demand for STD Testing Services?

The increasing awareness of sexual health and the rising prevalence of STDs, particularly among the younger population, are significantly influencing the demand for STD testing services. Educational campaigns and public health initiatives, particularly those targeting at-risk groups like young adults, LGBTQ+ communities, and sex workers, are emphasizing the importance of regular testing and early diagnosis. The shift towards preventive healthcare and personalized medicine is also playing a role, as healthcare providers advocate for proactive screening and routine check-ups to mitigate the spread of infections. Additionally, the expansion of telemedicine services, which offer convenient access to STD testing and consultations, is making testing more accessible and appealing, particularly in the wake of the COVID-19 pandemic, which accelerated the adoption of remote healthcare solutions. These trends indicate a growing acceptance and demand for routine STD testing as part of comprehensive healthcare management.

What Factors Are Driving the Growth of the STD Testing Market?

The growth in the STD testing market is driven by several factors, including the rising prevalence of STDs, technological advancements in diagnostic tools, and the increasing emphasis on preventive healthcare. The expansion of point-of-care testing technologies and the availability of at-home testing kits are making testing more accessible, particularly for individuals who prefer privacy and convenience. The integration of molecular diagnostics, which enhances the accuracy and speed of test results, is attracting healthcare providers looking for efficient ways to manage and prevent the spread of infections. Public health initiatives and educational campaigns are also expanding testing access, particularly in developing regions where healthcare infrastructure is improving. Additionally, the widespread adoption of telemedicine services is facilitating remote consultations and access to testing, further supporting market growth. These combined factors are propelling the expansion of the STD testing market, making it a critical component of modern healthcare.

Select Competitors (Total 47 Featured) -
  • Alere, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
STD Testing – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence of Sexually Transmitted Diseases (STDs) Worldwide
Increasing Demand for Rapid and Point-of-Care Testing Solutions
Growth in Awareness Campaigns Promoting Routine STD Testing
Expansion of At-Home Testing Kits for Privacy and Convenience
Surge in Telemedicine Services Facilitating Remote STD Testing
Technological Advancements in Multiplex and PCR-Based Tests
Growing Focus on Early Detection and Preventive Healthcare
Rising Use of Mobile Health (mHealth) Apps for Test Scheduling and Results
Development of Combination Test Kits Covering Multiple STDs
Increasing Availability of Affordable STD Testing Solutions in Emerging Markets
Growth in Use of Self-Collection Kits for Enhanced Patient Comfort
Rising Collaboration Between Public Health Organizations and Testing Providers
Expansion of Laboratory Infrastructure Supporting High-Volume Testing
Surge in Demand for Digital Platforms Offering Confidential STD Testing
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World STD Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for STD Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Chlamydia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Chlamydia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Herpes Simplex Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Herpes Simplex Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Gonorrhea by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Gonorrhea by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Human Papillomavirus (HPV) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Human Papillomavirus (HPV) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Syphilis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Syphilis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Laboratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Laboratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Point-of-Care (POC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Point-of-Care (POC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
JAPAN
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
CHINA
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
EUROPE
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for STD Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
FRANCE
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
GERMANY
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
UNITED KINGDOM
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
ASIA-PACIFIC
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for STD Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
AUSTRALIA
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
INDIA
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
LATIN AMERICA
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for STD Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
MIDDLE EAST
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for STD Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for STD Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for STD Testing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
AFRICA
STD Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for STD Testing by Disease Type - Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for STD Testing by Disease Type - Percentage Breakdown of Value Sales for Chlamydia, Herpes Simplex Virus, Gonorrhea, Human Papillomavirus (HPV), Syphilis and Other Disease Types for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for STD Testing by Location - Laboratory and Point-of-Care (POC) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for STD Testing by Location - Laboratory and Point-of-Care (POC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for STD Testing by Location - Percentage Breakdown of Value Sales for Laboratory and Point-of-Care (POC) for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings